“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Evolva
Edison Investment Research is terminating coverage on Evolva. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
Evolva — 2 videos in collection
Evolva is a Swiss biotech company focused on the research, development and commercialisation of ingredients based on nature. It has leading businesses in flavours and fragrances, health ingredients and health protection. Evolva’s proprietary fermentation-based technology allows for the large-scale production of ingredients that would otherwise be prohibitively expensive. Over the past few years, Evolva has transformed from an R&D-driven enterprise to a commercial company with a product-based revenue model. Its goal is to be cash break-even by FY23.
Get access to the very latest content matched to your personal investment style.
